Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T L Wright

Showing results (141-150 of 149) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 149 results.
Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 29, 1998
Hepatitis after liver transplantation: the role of the known and unknown virusesM G Pessoa, N A Terrault, L D Ferrell, et al.
Hepatology (Baltimore, Md.)|July 1, 1992
Intracranial pressure monitoring and liver transplantation for fulminant hepatic failureS D Lidofsky, N M Bass, M C Prager, et al.
The American Journal of Gastroenterology|November 30, 2000
A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotypeM W Fried, M Shiffman, R K Sterling, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 11, 2006
Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantationC-K Hui, E Lau, A Monto, et al.
The New England Journal of Medicine|December 7, 2000
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosisE J Heathcote, M L Shiffman, W G Cooksley, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2002
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infectionR G Gish, N W Y Leung, T L Wright, et al.
Hepatology (Baltimore, Md.)|May 1, 1997
Hepatitis G virus in patients with cryptogenic liver disease undergoing liver transplantationM G Pessoa, N A Terrault, L D Ferrell, et al.
Hepatology (Baltimore, Md.)|February 15, 2001
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis CK R Reddy, T L Wright, P J Pockros, et al.
Journal of Viral Hepatitis|April 14, 2006
Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*N Bräu, E J Bini, S Currie, et al.
Pageof 15

Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 29, 1998
Hepatitis after liver transplantation: the role of the known and unknown virusesM G Pessoa, N A Terrault, L D Ferrell, et al.
Hepatology (Baltimore, Md.)|July 1, 1992
Intracranial pressure monitoring and liver transplantation for fulminant hepatic failureS D Lidofsky, N M Bass, M C Prager, et al.
The American Journal of Gastroenterology|November 30, 2000
A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotypeM W Fried, M Shiffman, R K Sterling, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 11, 2006
Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantationC-K Hui, E Lau, A Monto, et al.
The New England Journal of Medicine|December 7, 2000
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosisE J Heathcote, M L Shiffman, W G Cooksley, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2002
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infectionR G Gish, N W Y Leung, T L Wright, et al.
Hepatology (Baltimore, Md.)|May 1, 1997
Hepatitis G virus in patients with cryptogenic liver disease undergoing liver transplantationM G Pessoa, N A Terrault, L D Ferrell, et al.
Hepatology (Baltimore, Md.)|February 15, 2001
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis CK R Reddy, T L Wright, P J Pockros, et al.
Journal of Viral Hepatitis|April 14, 2006
Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*N Bräu, E J Bini, S Currie, et al.
Pageof 15